{
    "clinical_study": {
        "@rank": "164951", 
        "acronym": "SAFEGUARD", 
        "arm_group": [
            {
                "arm_group_label": "GLP-1 agonist", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "DPP-4 inhibitor", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Sulfonylurea derivate", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the effects of incretin-based antidiabetic therapies\n      (DPP-4 inhibitors and GLP-1 agonists) on cardiovascular, gastrointestinal and renal system\n      and to detail the mechanisms underlying their action in these systems."
        }, 
        "brief_title": "Safety Evaluation of Adverse Reactions in Diabetes", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 2 diabetes mellitus\n\n          -  Metformin monotherapy - stable dose during last 3 months\n\n          -  HbA1C 48-75 mmol/mol (IFCC)\n\n          -  BMI 25-40 kg/m2\n\n          -  Age 35-70 years (women postmenopausal)\n\n          -  Use of ACE inhibitors or ATII receptor blockers for at least 3 months before\n             enrollment\n\n        Exclusion Criteria:\n\n          -  eGFR<30 ml/min/1.73m2 (MDRD)\n\n          -  Treatment with incretin mimetics during 3 months before enrollment\n\n          -  Chronic insulin therapy\n\n          -  Chronic use of loop diuretics, glucocorticoids, NSAID, immune suppressants,\n             antimicrobial agents, chemotherapeutics, bile acid sequestrants (colestyramin,\n             colesevelam)\n\n          -  History of pancreatic disease or impaired pancreatic function (defined as the need to\n             use pancreatic enzymes)\n\n          -  Active liver disease or a 3-fold elevation of liver transaminases (ALT, AST)\n\n          -  Active malignancy\n\n          -  History of severe cardiovascular disease including acute coronary syndrome, stroke or\n             transient ischemic neurologic disorder during previous 6 months, atrial fibrillation\n             or other arrhythmia requiring chronic antiarrhythmic medication, chronic heart\n             failure (New York Heart Association grade III/IV)\n\n          -  History of alcohol abuse, defined as >4 units of alcohol/day (32 g or 40 ml of 100%\n             alcohol)\n\n          -  History of allergy for GLP-1 receptor agonists or DPP-4 inhibitors\n\n          -  Any disease that could interfere with study procedures (e.g. decreased mobility,\n             mental incapacity)\n\n          -  Inability to give informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02092597", 
            "org_study_id": "HEALTH-282521-CUNI"
        }, 
        "intervention": [
            {
                "arm_group_label": "GLP-1 agonist", 
                "intervention_name": "Exenatide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "DPP-4 inhibitor", 
                "intervention_name": "Linagliptin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sulfonylurea derivate", 
                "intervention_name": "Gliclazide", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Exenatide", 
                "BI 1356", 
                "Gliclazide"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 19, 2014", 
        "location": {
            "contact": {
                "email": "milos_mraz@yahoo.co.uk", 
                "last_name": "Milos Mraz, MD PhD", 
                "phone": "+420 224 96 28 84"
            }, 
            "facility": {
                "address": {
                    "city": "Prague", 
                    "country": "Czech Republic", 
                    "zip": "128 08"
                }, 
                "name": "General University Hospital"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Czech Republic"
        }, 
        "number_of_arms": "3", 
        "overall_contact": {
            "email": "mhalu@fl1.cuni.cz", 
            "last_name": "Martin Hauzik, MD DSc", 
            "phone": "+420 224 96 29 08"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Czech Republic: State Drug Agency"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Heart rate", 
                "time_frame": "90 days after treatment initiation"
            }, 
            {
                "measure": "Gastric evacuation velocity", 
                "time_frame": "90 days after treatment initiation"
            }, 
            {
                "measure": "Blood pressure", 
                "time_frame": "90 days after treatment initiation"
            }, 
            {
                "measure": "Left ventricular ejection fraction", 
                "time_frame": "90 days after treatment initiation"
            }, 
            {
                "measure": "Intimomedial thickness", 
                "time_frame": "90 days after treatment initiation"
            }, 
            {
                "measure": "Pulse wave velocity", 
                "time_frame": "90 days after treatment initiation"
            }, 
            {
                "measure": "Glomerular filtration rate", 
                "time_frame": "90 days after treatment initiation"
            }, 
            {
                "measure": "Tubular function", 
                "time_frame": "90 days after treatment initiation"
            }, 
            {
                "description": "Marker of renal damage", 
                "measure": "KIM-1", 
                "time_frame": "90 days after treatment initiation"
            }, 
            {
                "measure": "Exocrine pancreas function", 
                "time_frame": "90 days after treatment initiation"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02092597"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Charles University, Czech Republic", 
            "investigator_full_name": "Martin Haluzik", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Charles University, Czech Republic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Charles University, Czech Republic", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}